Simcere Pharmaceutical Group Limited (HKG:2096)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
12.10
-0.15 (-1.22%)
Apr 28, 2026, 4:08 PM HKT
41.85%
Market Cap 31.64B
Revenue (ttm) 8.60B
Net Income (ttm) 1.50B
Shares Out 2.58B
EPS (ttm) 0.60
PE Ratio 20.39
Forward PE 13.69
Dividend 0.21 (1.69%)
Ex-Dividend Date Jun 17, 2026
Volume 3,840,430
Average Volume 9,929,353
Open 12.14
Previous Close 12.25
Day's Range 12.00 - 12.46
52-Week Range 8.24 - 15.08
Beta 0.79
RSI 39.37
Earnings Date May 8, 2026

About HKG:2096

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENW... [Read more]

Sector Healthcare
Founded 1995
Employees 7,038
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2096
Full Company Profile

Financial Performance

In 2025, HKG:2096's revenue was 7.73 billion, an increase of 16.52% compared to the previous year's 6.64 billion. Earnings were 1.34 billion, an increase of 83.32%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.